Efficacy and Durability of Combination Treatment With Glucagon-Like Peptide-1 Receptor Agonists and Basal Insulin

Abstract

Get full access to this article

View all access options for this article.

References

American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(suppl 1):S125-S143. doi:10.2337/dc22-S009

Skolnik

Hinnen

Kiriakov

Magwire

White

Jr.

Initiating titratable fixed-ratio combinations of basal insulin analogs and glucagon-like peptide-1 receptor agonists: what you need to know. Clin Diabetes. 2018;36(2):174-182. doi:10.2337/cd17-0048

Blonde

Anderson

Chava

Dendy

JA.

Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):793-804.

Tsapas

Karagiannis

Kakotrichi

, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23:2116-2124.

Chubb

Gupta

, et al. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: Systematic review and network meta-analysis. Diabetes Ther. 2021;12(5):1325-1339. doi:10.1007/s13300-021-01034-w